These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 17078068)

  • 21. Direct and indirect pathways in levodopa-induced dyskinesia: a more complex matter than a network imbalance.
    Ghiglieri V; Picconi B; Calabresi P
    Mov Disord; 2010 Aug; 25(11):1527-9. PubMed ID: 20623774
    [No Abstract]   [Full Text] [Related]  

  • 22. Wearing-off phenomena and levodopa-induced dyskinesias in posttraumatic hemiparkinsonism.
    Pita Lobo P; Coelho M; Mestre TA; Rosa MM; Ferreira JJ
    Mov Disord; 2013 Aug; 28(9):1212-4. PubMed ID: 23861327
    [No Abstract]   [Full Text] [Related]  

  • 23. Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976-1990.
    Van Gerpen JA; Kumar N; Bower JH; Weigand S; Ahlskog JE
    Arch Neurol; 2006 Feb; 63(2):205-9. PubMed ID: 16476808
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Riluzole for levodopa-induced dyskinesias in advanced Parkinson's disease.
    Merims D; Ziv I; Djaldetti R; Melamed E
    Lancet; 1999 May; 353(9166):1764-5. PubMed ID: 10347995
    [No Abstract]   [Full Text] [Related]  

  • 25. Amantadine for levodopa-induced choreic dyskinesia in compound heterozygotes for GCH1 mutations.
    Furukawa Y; Filiano JJ; Kish SJ
    Mov Disord; 2004 Oct; 19(10):1256-8. PubMed ID: 15389992
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Parkinson's disease.
    Marsden CD
    Lancet; 1990 Apr; 335(8695):948-52. PubMed ID: 1691427
    [No Abstract]   [Full Text] [Related]  

  • 27. Age at onset influences neurodegenerative processes underlying PD with levodopa-induced dyskinesias.
    Cerasa A; Salsone M; Morelli M; Pugliese P; Arabia G; Gioia CM; Novellino F; Quattrone A
    Parkinsonism Relat Disord; 2013 Oct; 19(10):883-8. PubMed ID: 23769805
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Botulinum toxin type A for Levodopa-induced cervical dyskinesias in Parkinson's disease: unfavorable risk-benefit ratio.
    Espay AJ; Vaughan JE; Shukla R; Gartner M; Sahay A; Revilla FJ; Duker AP
    Mov Disord; 2011 Apr; 26(5):913-4. PubMed ID: 21432906
    [No Abstract]   [Full Text] [Related]  

  • 29. The role of apolipoprotein E polymorphisms in levodopa-induced dyskinesia.
    Molchadski I; Korczyn AD; Cohen OS; Katzav A; Nitzan Z; Chapman J; Hassin-Baer S
    Acta Neurol Scand; 2011 Feb; 123(2):117-21. PubMed ID: 21108621
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dyskinesias during levodopa-carbidopa intestinal gel (LCIG) infusion: Management inclinical practice.
    Melgari JM; Salomone G; di Biase L; Marano M; Scrascia F; Di Lazzaro V
    Parkinsonism Relat Disord; 2015 Mar; 21(3):327-8. PubMed ID: 25595317
    [No Abstract]   [Full Text] [Related]  

  • 31. Role of receptor heterodimers in the development of L-dopa-induced dyskinesias in the 6-hydroxydopamine rat model of Parkinson's disease.
    Fiorentini C; Busi C; Spano P; Missale C
    Parkinsonism Relat Disord; 2008; 14 Suppl 2():S159-64. PubMed ID: 18638717
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Problems and future perspectives in the treatment of Parkinson's disease].
    Hens L; Hellemans J
    Tijdschr Gerontol Geriatr; 1982 Aug; 13(4):147-54. PubMed ID: 6127822
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of levetiracetam on levodopa induced dyskinesia in patients with Parkinson's disease.
    Tousi B; Subramanian T
    Parkinsonism Relat Disord; 2005 Aug; 11(5):333-4. PubMed ID: 15949966
    [No Abstract]   [Full Text] [Related]  

  • 34. Molecular mechanisms of L-DOPA-induced dyskinesia.
    Jenner P
    Nat Rev Neurosci; 2008 Sep; 9(9):665-77. PubMed ID: 18714325
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dyskinesias assessment: from CAPIT to CAPSIT. Core Assessment Program for Intracerebral Transplantations. Core Assessment Program for Surgical Interventional Therapies.
    Widner H; Defer GL
    Mov Disord; 1999; 14 Suppl 1():60-6. PubMed ID: 10493405
    [No Abstract]   [Full Text] [Related]  

  • 36. Development of dyskinesias in a 5-year trial of ropinirole and L-dopa.
    Rascol O; Brooks DJ; Korczyn AD; De Deyn PP; Clarke CE; Lang AE; Abdalla M;
    Mov Disord; 2006 Nov; 21(11):1844-50. PubMed ID: 16958094
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical pharmacology of levodopa-induced dyskinesia in parkinsonian patients.
    Rascol O; Brefel-Courbon C; Descombes S; Montastruc JL
    Adv Neurol; 1999; 80():485-90. PubMed ID: 10410760
    [No Abstract]   [Full Text] [Related]  

  • 38. Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments.
    Encarnacion EV; Hauser RA
    Eur Neurol; 2008; 60(2):57-66. PubMed ID: 18480609
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Rush dyskinesia scale or Goetz scale].
    Krystkowiak P; Defebvre L
    Rev Neurol (Paris); 2002 May; 158(5 Pt 1):622-4. PubMed ID: 12072837
    [No Abstract]   [Full Text] [Related]  

  • 40. CLINICAL TRIAL HIGHLIGHTS - DYSKINESIA.
    McFarthing K; Prakash N; Simuni T
    J Parkinsons Dis; 2019; 9(3):449-465. PubMed ID: 31356217
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.